Cargando…

Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?

OBJECTIVE: It is unclear whether the receptor status of breast malignancy or the proportion of receptors expression is useful in the interpretation of (18)F-FDG PET/CT. This study’s purpose was to analyze whether (18)F-FDG PET/CT was valuable for helping newly diagnosed breast cancer patients find s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiachen, Sun, Runlu, Yin, Yuping, Li, Jingyan, Liu, Xuming, Liu, Sheng, Zhang, Zhanlei, Hu, Jieting, Wan, Xiaoting, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599817/
https://www.ncbi.nlm.nih.gov/pubmed/34804947
http://dx.doi.org/10.3389/fonc.2021.755899
_version_ 1784601025410236416
author Liu, Jiachen
Sun, Runlu
Yin, Yuping
Li, Jingyan
Liu, Xuming
Liu, Sheng
Zhang, Zhanlei
Hu, Jieting
Wan, Xiaoting
Zhang, Hong
author_facet Liu, Jiachen
Sun, Runlu
Yin, Yuping
Li, Jingyan
Liu, Xuming
Liu, Sheng
Zhang, Zhanlei
Hu, Jieting
Wan, Xiaoting
Zhang, Hong
author_sort Liu, Jiachen
collection PubMed
description OBJECTIVE: It is unclear whether the receptor status of breast malignancy or the proportion of receptors expression is useful in the interpretation of (18)F-FDG PET/CT. This study’s purpose was to analyze whether (18)F-FDG PET/CT was valuable for helping newly diagnosed breast cancer patients find suspected or unsuspected metastasis lesions based on the proportion of receptors expression. MATERIALS AND METHODS: Eighty newly diagnosed breast cancer patients were divided into six groups, containing N0 (no extraaxillary lymph node metastasis), N1 (extraaxillary lymph node metastasis), M0 (no distant metastasis), and M1 (distant metastasis) groups, C0 (no unsuspected metastasis), and C1 (unsuspected metastasis and treatment plan changed) detected by PET/CT. The main data, including the proportion of receptors ER (estrogen receptor), PR (progesterone receptor), and Her-2 (human epidermal growth factor receptor 2) status, were extracted. Simple correlation and logistic regression were preformed to analyze the association between them. RESULTS: Patients in N1 group had lower proportion of ER (%) and PR (%) than that in N0 group (ER: 2 [0–80] vs. 80 [15–95]; PR: 1 [0–10] vs. 20 [0–45], p<0.001). Moreover, the proportions of ER and PR were negatively correlated with N1 (ER: [r= −0.339, p= 0.002], PR: [r= −0.247, p= 0.011]) by simple correlation. Also, patients in C1 group had lower proportion of ER (%) and PR (%) than those in C0 group (ER: 10 [0–85] vs. 80 [15–90], p=0.026; PR: 1 [0–10] vs. 20 [0–70], p=0.041), while the distribution of ER and PR between M1 and M0 group had no significant difference. After the adjustment of traditional factors, the negative correlation between the proportion of ER (OR=0.986, 95% CI of OR [0.972–0.999], p=0.016) and C1 was found by logistic regression, cutoff value was 25% (ER) calculated by ROC (Receiver Operating Characteristic) curve (AUC [Area Under Curve]= 0.647, p=0.024). CONCLUSION: The proportion of ER in newly diagnosed breast cancer was negatively correlated with unsuspected metastasis detected by (18)F-FDG PET/CT. (18)F-FDG PET/CT might be recommended for newly diagnosed breast cancer patients with single lesions when the ER expression proportion is less than 25% to find unsuspected metastasis lesions and to modify treatment plan contrasted with conventional imaging and clinical examination.
format Online
Article
Text
id pubmed-8599817
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85998172021-11-19 Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression? Liu, Jiachen Sun, Runlu Yin, Yuping Li, Jingyan Liu, Xuming Liu, Sheng Zhang, Zhanlei Hu, Jieting Wan, Xiaoting Zhang, Hong Front Oncol Oncology OBJECTIVE: It is unclear whether the receptor status of breast malignancy or the proportion of receptors expression is useful in the interpretation of (18)F-FDG PET/CT. This study’s purpose was to analyze whether (18)F-FDG PET/CT was valuable for helping newly diagnosed breast cancer patients find suspected or unsuspected metastasis lesions based on the proportion of receptors expression. MATERIALS AND METHODS: Eighty newly diagnosed breast cancer patients were divided into six groups, containing N0 (no extraaxillary lymph node metastasis), N1 (extraaxillary lymph node metastasis), M0 (no distant metastasis), and M1 (distant metastasis) groups, C0 (no unsuspected metastasis), and C1 (unsuspected metastasis and treatment plan changed) detected by PET/CT. The main data, including the proportion of receptors ER (estrogen receptor), PR (progesterone receptor), and Her-2 (human epidermal growth factor receptor 2) status, were extracted. Simple correlation and logistic regression were preformed to analyze the association between them. RESULTS: Patients in N1 group had lower proportion of ER (%) and PR (%) than that in N0 group (ER: 2 [0–80] vs. 80 [15–95]; PR: 1 [0–10] vs. 20 [0–45], p<0.001). Moreover, the proportions of ER and PR were negatively correlated with N1 (ER: [r= −0.339, p= 0.002], PR: [r= −0.247, p= 0.011]) by simple correlation. Also, patients in C1 group had lower proportion of ER (%) and PR (%) than those in C0 group (ER: 10 [0–85] vs. 80 [15–90], p=0.026; PR: 1 [0–10] vs. 20 [0–70], p=0.041), while the distribution of ER and PR between M1 and M0 group had no significant difference. After the adjustment of traditional factors, the negative correlation between the proportion of ER (OR=0.986, 95% CI of OR [0.972–0.999], p=0.016) and C1 was found by logistic regression, cutoff value was 25% (ER) calculated by ROC (Receiver Operating Characteristic) curve (AUC [Area Under Curve]= 0.647, p=0.024). CONCLUSION: The proportion of ER in newly diagnosed breast cancer was negatively correlated with unsuspected metastasis detected by (18)F-FDG PET/CT. (18)F-FDG PET/CT might be recommended for newly diagnosed breast cancer patients with single lesions when the ER expression proportion is less than 25% to find unsuspected metastasis lesions and to modify treatment plan contrasted with conventional imaging and clinical examination. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8599817/ /pubmed/34804947 http://dx.doi.org/10.3389/fonc.2021.755899 Text en Copyright © 2021 Liu, Sun, Yin, Li, Liu, Liu, Zhang, Hu, Wan and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Jiachen
Sun, Runlu
Yin, Yuping
Li, Jingyan
Liu, Xuming
Liu, Sheng
Zhang, Zhanlei
Hu, Jieting
Wan, Xiaoting
Zhang, Hong
Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?
title Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?
title_full Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?
title_fullStr Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?
title_full_unstemmed Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?
title_short Is (18)F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?
title_sort is (18)f-fdg pet/ct beneficial for newly diagnosed breast cancer patients with low proportion of er expression?
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599817/
https://www.ncbi.nlm.nih.gov/pubmed/34804947
http://dx.doi.org/10.3389/fonc.2021.755899
work_keys_str_mv AT liujiachen is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT sunrunlu is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT yinyuping is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT lijingyan is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT liuxuming is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT liusheng is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT zhangzhanlei is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT hujieting is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT wanxiaoting is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression
AT zhanghong is18ffdgpetctbeneficialfornewlydiagnosedbreastcancerpatientswithlowproportionoferexpression